Daptomycin: Evaluation of a high-dose treatment strategy

International Journal of Antimicrobial Agents

Volumn 38, Issue 3, 2011, Pages 192-196

  Wu, Gary ^a   Abraham, Teena ^a   Rapp, Jonathan ^a   Vastey, Fabienne ^a   Saad, Nasser ^a   Balmir, Eric ^a  

^a NEW YORK METHODIST HOSPITAL   (United States)

Author keywords

Antibiotic resistance; Daptomycin; High dose daptomycin; Lipopeptide

Indexed keywords

DAPTOMYCIN; PENICILLIN G; PLACEBO; VANCOMYCIN;

ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; APHTHOUS STOMATITIS; AREA UNDER THE CURVE; ARTHRALGIA; BACTERIAL ENDOCARDITIS; CLINICAL EVALUATION; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROSTHESIS INFECTION; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; STRATEGIC PLANNING; TREATMENT DURATION; TREATMENT PLANNING; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 80051552597     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.03.006     Document Type: Short Survey

References (29)

1. R.L. Akins, and K.K. Haase Gram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists Pharmacotherapy 25 2005 1001 1010 (Pubitemid 40917932)
2. D.J. Farrell, R.E. Mendes, J.E. Ross, and R.N. Jones Linezolid surveillance program results for 2008 (LEADER Program for 2008) Diagn Microbiol Infect Dis 65 2009 392 403
3. A. Soriano, F. Marco, J.A. Martínez, E. Pisos, M. Almela, and V.P. Dimova Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia Clin Infect Dis 46 2008 193 200 (Pubitemid 351269157)
4. G. Sakoulas, P.A. Moise-Broder, J. Schentag, A. Forrest, R.C. Moellering Jr., and G.M. Eliopoulos Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia J Clin Microbiol 42 2004 2398 2402 (Pubitemid 38747480)
5. P.A. Moise, E. Hershberger, M.I. Amodio-Groton, and K.C. Lamp Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy Ann Pharmacother 43 2009 1211 1219
6. K.L. Tedesco, and M.J. Rybak Daptomycin Pharmacotherapy 24 2004 41 57 (Pubitemid 38056251)
7. B.H. Dvorchik, D. Brazier, M.F. DeBruin, and R.D. Arbeit Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects Antimicrob Agents Chemother 47 2003 1318 1323 (Pubitemid 36368592)
8. Cubist Pharmaceuticals Cubicin (daptomycin) package insert 2010 Cubist Pharmaceuticals Lexington, MA
9. K. Julian, K. Kosowska-Shick, C. Whitener, M. Roos, H. Labischinski, and A. Rubio Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis Antimicrob Agents Chemother 51 2007 3445 3448 (Pubitemid 350067576)
10. A.I. Hidron, A.N. Schuetz, F.S. Nolte, C.V. Gould, and M.K. Osborn Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis J Antimicrob Chemother 61 2008 1394 1396 (Pubitemid 351753616)
11. J.S. Lewis 2nd, A. Owens, J. Cadena, K. Sabol, J.E. Patterson, and J.H. Jorgensen Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy Antimicrob Agents Chemother 49 2005 1664 1665 (Pubitemid 40463418)
12. M. Benvenuto, D.P. Benziger, S. Yankelev, and G. Vigliani Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers Antimicrob Agents Chemother 50 2006 3245 3249 (Pubitemid 44527494)
13. D.E. Katz, K.C. Lindfield, J.N. Steenbergen, D.P. Benziger, K.J. Blackerby, and A.G. Knapp A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by Gram-positive bacteria Int J Clin Pract 62 2008 1455 1464
14. D.A. Figueroa, E. Mangini, M. Amodio-Groton, B. Vardianos, A. Melchert, and C. Fana Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program Clin Infect Dis 49 2009 177 180
15. M. Bassetti, E. Nicco, F. Ginocchio, F. Ansaldi, D. de Florentiis, and C. Viscoli High-dose daptomycin in documented Staphylococcus aureus infections Int J Antimicrob Agents 36 2010 459 461
16. B.A. Cunha, V. Krol, and V. Kodali Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin Heart Lung 37 2008 72 75
17. A.C. Schutt, and N.M. Bohm Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin Ann Pharmacother 43 2009 2108 2112
18. B.A. Cunha, L.E. Eisenstein, and N.S. Hamid Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicity Heart Lung 35 2006 207 211
19. F.G. De Rosa, O. Mollaretti, C. Cometto, N. Pagani, C. Montrucchio, and G. Di Perri Early experience with high dosage daptomycin for prosthetic infections Clin Infect Dis 49 2009 1772 1773
20. M. Lichterfeld, M.J. Ferraro, and B.T. Davis High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides Int J Antimicrob Agents 35 2010 96
21. F.P. Tally, and M.F. Debruin Development of daptomycin for Gram-positive infections J Antimicrob Chemother 46 2000 523 526
22. C.F. Carpenter, and H.F. Chambers Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens Clin Infect Dis 38 2004 994 1000 (Pubitemid 38457208)
23. B.I. Eisenstein, F.B. Oleson Jr., and R.H. Baltz Daptomycin: from the mountain to the clinic with essential help from Francis Tally, MD Clin Infect Dis 50 Suppl. 1 2010 S10 S15
24. R. Cha, R.G. Grucz, and M.J. Rybak Daptomycin dose-effect relationship against resistant Gram-positive organisms Antimicrob Agents Chemother 47 2003 1598 1603 (Pubitemid 36548543)
25. H.W. Boucher, and G. Sakoulas Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus Clin Infect Dis 45 2007 601 608 (Pubitemid 47328642)
26. R. Sauermann, M. Rothenburger, W. Graninger, and C. Joiukhader Daptomycin: a review 4 years after first approval Pharmacology 81 2008 79 91 (Pubitemid 351182681)
27. V.G. Fowler Jr., H.W. Boucher, G.R. Corey, E. Abrutyn, A.W. Karchmer, and M.E. Rupp Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus N Engl J Med 355 2006 653 665
28. W.E. Rose, S.N. Leonard, and M.J. Rybak Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations J Antimicrob Chemother 52 2008 3061 3067
29. W.E. Rose, M.J. Rybak, and G.W. Kaatz Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies J Antimicrob Chemother 60 2007 334 340 (Pubitemid 47243883)